The funding will be used in multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), to prevent disease and death from exposure to anthrax when administered intramuscularly before symptoms of disease are present.
Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack.
Elusys president and CEO Elizabeth Posillico said in several animal studies conducted to date, ETI-204 has demonstrated excellent efficacy and increased survival significantly when given in a single intramuscular dose.
Elusys Research vice president Leslie Casey said in a recent animal study, a single IM dose of Anthim provided a 92% survival rate when administered 18 hours after exposure to anthrax.